WALTHAM, Mass. – March 30, 2016 – X-Chem, Inc. (X-Chem), a privately held biotechnology company applying its innovative DNA-Encoded X-Chem (DEX™) drug discovery platform to generate novel therapeutics, today announced that a licensing option with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has been exercised for a protein inhibitor […]
Author Archive | xchem-editor
WALTHAM, Mass. – January 6 , 2015 – X-Chem, Inc., a privately held biotechnology company applying its cutting-edge lead discovery capabilities to the generation of novel small molecule therapeutics, announced a multi-target collaboration with Sanofi. The collaboration is focused on the potential development of several programs for treatments in therapeutic areas such as oncology, rare […]
WALTHAM, Mass. – January 6, 2016 –X-Chem, Inc., a privately held biotechnology company with a proprietary and innovative platform to generate small molecule therapeutics, today announced a multi-target agreement with The University of Texas MD Anderson Cancer Center […]
WALTHAM, Mass. – January 6, 2016 –X-Chem announced today that it has been spun out to the shareholders of the parent company of Pharmaceutical Product Development, LLC (“PPD”) as an independent, privately-owned biotechnology company.
Jun 10, 2015|Sci. Rep.|Encoded Library Synthesis Using Chemical Ligation and the Discovery of sEH Inhibitors from a 334-Million Member Library. A chemical ligation method for construction of DNA-encoded small-molecule libraries has been developed. Taking advantage of the ability of the Klenow fragment of DNA polymerase to accept templates with triazole linkages in place of phosphodiesters, […]
June 2015|Curr Opin Chem Biol.|Chemical ligation methods for the tagging of DNA-encoded chemical libraries. The generation of DNA-encoded chemical libraries requires the unimolecular association of multiple encoding oligonucleotides with encoded chemical entities during combinatorial synthesis processes. This has traditionally been achieved using enzymatic ligation. We discuss a range of chemical ligation methods that provide alternatives […]
WALTHAM & CAMBRIDGE, Mass. – March 30, 2015 –X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery platform to the generation of novel small molecule therapeutics, today announced that Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling, exercised its option to obtain an exclusive […]